Last updated: September 3, 2026
Premphase is a fixed-cycle hormone replacement product combining conjugated estrogens, marketed as Premarin, with medroxyprogesterone acetate, marketed as Cycrin. The 14/14 regimen contains 14 days of conjugated estrogens followed by 14 days of conjugated estrogens plus medroxyprogesterone acetate. Its commercial value is limited relative to the broader Premarin franchise because Pfizer does not separately report Premphase revenue, prescription volume, or profit.
The product operates in a mature, declining hormone-replacement market. Its principal risks are generic substitution, reduced use of oral estrogen therapy, safety-driven prescribing constraints, and migration toward lower-cost estrogen-progestin alternatives. Premphase has no identifiable modern patent barrier capable of supporting premium pricing or delaying generic competition.
What is Premphase and how does the Premarin-Cycrin 14/14 regimen work?
Premphase is an oral, cyclic hormone replacement therapy. The standard regimen supplies:
| Component |
Premphase 14/14 regimen |
| Conjugated estrogens |
0.625 mg daily for 14 days |
| Conjugated estrogens plus medroxyprogesterone acetate |
0.625 mg / 5 mg daily for 14 days |
| Cycle length |
28 days |
| Primary therapeutic category |
Menopausal hormone therapy |
| Principal sponsor |
Pfizer |
| Estrogen brand |
Premarin |
| Progestin brand |
Cycrin |
The estrogen component is indicated for menopausal vasomotor symptoms and vulvar and vaginal atrophy. The progestin component is used with estrogen in women with an intact uterus to reduce the risk of endometrial hyperplasia associated with unopposed estrogen exposure.[1]
Premphase differs from Prempro, another Pfizer product, because Prempro provides estrogen and progestin together continuously or in fixed-dose formulations. Premphase uses a sequential regimen, with progestin exposure limited to the latter half of the cycle.
How does Premphase compare with Prempro?
| Product |
Regimen structure |
Estrogen |
Progestin |
Commercial implication |
| Premphase |
Sequential 14/14 |
Conjugated estrogens |
Medroxyprogesterone acetate |
Targets patients prescribed cyclic therapy |
| Prempro |
Continuous or fixed combination |
Conjugated estrogens |
Medroxyprogesterone acetate |
Broader combination-product positioning |
| Generic estradiol plus medroxyprogesterone |
Usually separate products or alternative combinations |
Estradiol |
Medroxyprogesterone acetate or another progestogen |
Lower-cost substitution risk |
| Bijuva |
Continuous fixed combination |
Estradiol |
Progesterone |
Competes on formulation and tolerability |
| Duavee |
Fixed combination |
Conjugated estrogens |
Bazedoxifene |
Competes where avoidance of progestin is commercially relevant |
Premphase’s sequential dosing remains clinically relevant for some patients, but its regimen is less convenient than continuous combination products and separate generic tablets.
What is the FDA regulatory status of Premphase?
Premphase is an FDA-approved prescription hormone replacement product. Its regulatory foundation is an older new drug application covering conjugated estrogens and medroxyprogesterone acetate in a cyclic pack.[1]
FDA approval does not guarantee current commercial availability. For mature products, the relevant distinction is between:
- An NDA that remains approved in FDA records.
- A product that is actively manufactured and distributed.
- A product that has meaningful retail or mail-order availability.
Premphase is a low-volume product within Pfizer’s women’s health portfolio. Public Pfizer filings do not identify Premphase as a separately reported product or disclose its current net sales. FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, should be reviewed for the current marketing and patent-listing record.[2]
What is the Orange Book status of Premphase?
Premphase is an old small-molecule combination product. Its commercial position is not based on an active composition-of-matter patent for a newly discovered molecule.
The likely strategic implications are:
- No meaningful new-molecule patent term remains.
- Any historic formulation or packaging protection is unlikely to block generic competition.
- A generic entrant could challenge listed patents under Paragraph IV if any enforceable patents were listed.
- Labeling, manufacturing complexity, and limited market size are more significant barriers than patent exclusivity.
The regulatory value of Premphase lies in the approved combination and cyclic presentation, not in patent-protected molecular novelty.
When does Premphase lose exclusivity?
Premphase’s core exclusivity expired many years ago. Conjugated estrogens and medroxyprogesterone acetate have long been off-patent active ingredients, and the product is exposed to generic substitution.
The practical exclusivity timeline is:
| Period |
Commercial status |
| Original launch period |
Protected by regulatory approval and historical brand positioning |
| Post-patent period |
Generic competition becomes legally permissible |
| Current period |
Mature branded product with limited differentiation |
| Future outlook |
No identifiable patent event likely to create a new exclusivity window |
Premphase does not have the type of remaining patent estate associated with high-value specialty pharmaceuticals. Any current commercial protection comes from prescribing familiarity, physician preference, product availability, and the economics of manufacturing and distribution.
How many patents cover Premphase?
No material active patent estate is publicly associated with Premphase that would support a conventional patent-based exclusivity forecast. The product’s patent position should be analyzed separately from Premarin’s broader historical patent record and from patents covering other conjugated-estrogen products.
Potentially relevant rights include:
- Historical patents covering conjugated estrogen compositions.
- Formulation or tablet-manufacturing patents.
- Packaging and regimen-related claims.
- Patents covering other estrogen-progestin combinations.
- Manufacturing know-how relating to complex conjugated estrogen mixtures.
These rights do not necessarily block a generic Premphase-equivalent product. A patent covering a manufacturing process may create cost or supply constraints without preventing approval of a product made through a different process.
What formulations are protected by Premphase?
The commercial formulation is a two-part cyclic pack rather than a technologically complex delivery system. The product does not rely on a long-acting implant, transdermal reservoir, extended-release system, biologic process, or device-dependent delivery method.
The most relevant technical issues are:
- Maintaining dose uniformity across estrogen tablets.
- Maintaining dose uniformity across estrogen-progestin tablets.
- Preserving stability across the 28-day package.
- Demonstrating pharmaceutical equivalence and bioequivalence.
- Managing the complex composition of conjugated estrogens.
- Ensuring reliable supply of the estrogen active ingredient.
The conjugated estrogen component is more complex than a single synthetic molecule because it is a defined mixture of estrogenic substances. That complexity can raise development and manufacturing costs for generic applicants. It is not equivalent to patent protection.
Which companies are challenging Premphase?
No major public Paragraph IV litigation campaign directed specifically at Premphase is apparent in the standard public patent-litigation record. The main competitive pressure comes from products containing the same active ingredients or therapeutically substitutable estrogen-progestin regimens.
The competitive field includes:
- Generic conjugated estrogens tablets.
- Generic medroxyprogesterone acetate.
- Separate generic estradiol and progestin prescriptions.
- Generic oral hormone replacement combinations.
- Transdermal estrogen products.
- Vaginal estrogen products.
- Nonhormonal therapies for vasomotor symptoms.
- Newer combination products such as estradiol and progesterone formulations.
The absence of prominent Premphase-specific litigation is commercially meaningful. It suggests that the market is too small, the patent position too weak, or the expected return too limited to support an aggressive branded-versus-generic litigation strategy.
What patent litigation affects Premphase?
Patent litigation is not the primary value driver for Premphase. The product’s main legal risks are regulatory and commercial rather than patent-based.
Relevant litigation categories would include:
| Litigation category |
Relevance to Premphase |
| Paragraph IV patent challenge |
Limited unless current Orange Book patents are listed |
| Product liability |
Relevant because hormone replacement products carry long-term safety litigation exposure |
| False-marking or labeling disputes |
Low current significance |
| Manufacturing disputes |
Potentially relevant because conjugated estrogen supply is specialized |
| Antitrust or pay-for-delay disputes |
No major Premphase-specific settlement is publicly established |
| Trademark disputes |
Limited value relative to the active ingredients |
The major historical liability issue for the broader Premarin franchise has been hormone replacement therapy litigation related to breast cancer, cardiovascular events, stroke, and other risks. Product labeling incorporates the findings and limitations associated with the Women’s Health Initiative and related evidence.[1]
What is the financial trajectory of Premphase and the Premarin franchise?
Pfizer does not separately disclose Premphase revenue. Its financial performance must therefore be assessed through the broader Premarin-family disclosures and market structure.
The financial trajectory is mature-to-declining:
- Premarin historically generated substantial revenue as a leading branded menopausal hormone therapy.
- Generic competition reduced price and prescription economics.
- Women’s Health Initiative safety findings reduced long-term hormone replacement use.
- Physicians and patients shifted toward lower-dose, transdermal, vaginal, and nonhormonal options.
- Premphase’s cyclic format remained a narrow subset of the declining oral market.
- Pfizer’s reported revenue reflects the aggregate Premarin family rather than Premphase-specific performance.[3]
What are the revenue implications for Pfizer?
Premphase is unlikely to be a material standalone revenue contributor. Its value is better understood as part of a residual branded portfolio that may produce cash flow despite limited growth.
| Financial factor |
Effect on Premphase |
| Generic price competition |
Reduces net price and payer leverage |
| Small patient population |
Limits scale economics |
| Oral estrogen decline |
Reduces prescription demand |
| Established brand recognition |
Supports some physician and patient retention |
| Manufacturing complexity |
May preserve supply discipline |
| Lack of patent exclusivity |
Prevents durable premium pricing |
| Pfizer portfolio scale |
Supports distribution and contracting |
| Product discontinuation risk |
Increases if manufacturing economics deteriorate |
Premphase’s contribution to Pfizer’s total revenue is immaterial relative to products such as Eliquis, Prevnar, Ibrance, Vyndaqel, and other major franchises. Its financial importance is likely measured through portfolio margin and cash generation rather than growth.
How strong is the Premphase patent estate?
The patent estate is weak from an exclusivity perspective but potentially relevant from a manufacturing perspective.
Patent-strength assessment
| Dimension |
Assessment |
| Composition-of-matter protection |
Expired or commercially irrelevant |
| Formulation protection |
Limited practical significance |
| Method-of-use protection |
Weak as a barrier to generic substitution |
| Manufacturing know-how |
Potentially meaningful |
| Regulatory exclusivity |
Expired |
| Trademark value |
Moderate for Premarin, low for Premphase |
| Litigation deterrence |
Low |
| Generic launch resistance |
Low to moderate, depending on manufacturing capability |
The main technical barrier is the active ingredient’s composition and supply chain. Conjugated estrogens are not identical in development economics to a simple synthetic tablet. A generic sponsor must establish equivalence against a complex mixture and maintain a reliable source of active pharmaceutical ingredient.
That barrier can slow entry. It cannot provide the same protection as an enforceable patent or orphan-drug exclusivity period.
What generic entry risks exist for Premphase?
Generic entry risk is high in legal terms and moderate in practical terms.
A generic sponsor could pursue one of several routes:
- A full generic equivalent to the Premphase 14/14 regimen.
- Separate generic conjugated estrogen and medroxyprogesterone products.
- A therapeutically equivalent combination with a different packaging format.
- An authorized generic or licensed supply arrangement.
- A lower-cost alternative based on estradiol and another progestogen.
The most likely commercial substitution is not necessarily a direct Premphase clone. Physicians often prescribe separate generic estrogen and progestin products, allowing dose adjustment and avoiding the economics of a low-volume branded pack.
What generic launch scenarios are most likely?
| Scenario |
Probability profile |
Commercial effect |
| Direct 14/14 generic launch |
Possible but limited by market size |
Sharp price pressure on Premphase |
| Separate generic substitution |
Highly plausible |
Erodes brand demand without direct one-for-one replacement |
| Continued Pfizer supply with low promotion |
Plausible |
Stable but shrinking niche revenue |
| Commercial discontinuation |
Plausible if supply costs rise |
Prescribers migrate to alternatives |
| New branded cyclic formulation |
Unlikely |
Requires meaningful clinical or convenience differentiation |
How does Premphase compare with competing menopause therapies?
Premphase competes in a market where treatment decisions increasingly depend on route of administration, dose, symptom profile, and risk management.
| Product category |
Strength versus Premphase |
Weakness versus Premphase |
| Generic oral estradiol plus progestin |
Lower cost and flexible dosing |
Less convenient than a packaged cycle |
| Transdermal estrogen plus progestin |
May offer lower hepatic exposure and flexible dosing |
Requires separate products or patches |
| Vaginal estrogen |
Strong for local genitourinary symptoms |
Limited systemic treatment of hot flashes |
| Bijuva |
Fixed-dose oral combination |
Higher branded cost and different estrogen/progesterone profile |
| Duavee |
Estrogen plus bazedoxifene, no conventional progestin |
Different clinical positioning and cost |
| Nonhormonal drugs |
Avoid estrogen-related risks |
May be less effective for some symptoms |
Premphase’s strongest commercial attributes are brand recognition, an established FDA-approved regimen, and a prepackaged cycle. Its weaknesses are cost, oral administration, legacy safety concerns, limited modern differentiation, and generic availability.
What licensing deals affect Premphase?
No major recent licensing transaction specifically involving Premphase is publicly identified. The product is associated with Pfizer’s broader ownership and commercialization of the Premarin family following Pfizer’s acquisition of Wyeth.
The absence of a visible standalone licensing market reflects the product’s economics. A licensee would face:
- Limited market growth.
- Generic competition.
- Low likelihood of patent-driven price protection.
- Manufacturing and supply-chain obligations.
- Liability exposure associated with hormone replacement therapy.
- Competition from inexpensive generic regimens.
A regional commercialization deal could still be rational where Pfizer lacks direct distribution or where a partner can maintain a niche women’s health portfolio. A large upfront payment or strategic acquisition premium would be difficult to justify based on Premphase alone.
What manufacturing and intellectual-property barriers affect Premphase?
The primary operational barrier is the supply of conjugated estrogens. Premarin’s conjugated estrogen ingredient has historically been associated with a specialized biological source and tightly controlled manufacturing process. This creates a more concentrated supply chain than is typical for a conventional synthetic active ingredient.
The resulting barriers include:
- Qualification of the active ingredient source.
- Batch consistency.
- Analytical characterization of a multicomponent estrogen mixture.
- Regulatory comparability.
- Manufacturing scale.
- Supply continuity.
- Quality-control requirements.
These barriers can support a small number of suppliers even after patent expiry. They do not, by themselves, prevent generic development.
What is the commercial outlook for Premphase?
Premphase has a declining, niche outlook. The product can retain residual demand among patients and clinicians who prefer cyclic hormone therapy, but it lacks a credible growth catalyst.
The base-case trajectory is:
- Continued erosion from generic and therapeutic substitution.
- Minimal promotional investment.
- Stable-to-declining availability.
- No meaningful patent-driven price increase.
- Greater dependence on supply economics and portfolio rationalization.
- Revenue contribution that remains small within Pfizer’s established-products business.
Upside would require a renewed market shift toward cyclic conjugated-estrogen therapy, which is unlikely without new clinical evidence or a significant change in prescribing practice. Downside would arise from manufacturing interruptions, additional generic supply, payer exclusion, or discontinuation of the branded pack.
Key Takeaways
- Premphase is a cyclic 14/14 hormone replacement product containing conjugated estrogens and medroxyprogesterone acetate.
- Pfizer does not publicly report Premphase revenue separately.
- Its financial performance is embedded in the broader Premarin-family portfolio.
- The product’s exclusivity is effectively expired; no material modern patent barrier is evident.
- Generic substitution risk is high, especially through separate generic estrogen and progestin prescriptions.
- Manufacturing complexity around conjugated estrogens is more important than patent protection.
- No major Premphase-specific Paragraph IV litigation or settlement is publicly established.
- Premphase has a mature, declining commercial profile and limited strategic value outside residual portfolio cash flow.
- Premarin retains greater brand and portfolio value than Premphase because it covers the broader conjugated-estrogen franchise.
- The most likely long-term outcome is continued niche availability or commercial discontinuation rather than renewed growth.
FAQs
Is Premphase the same as Prempro?
No. Premphase uses a sequential 14/14 regimen, while Prempro is a continuous or fixed combination of conjugated estrogens and medroxyprogesterone acetate.
Does Premphase have a generic equivalent?
Generic substitution can occur through conjugated estrogens and medroxyprogesterone acetate products, even where a direct 14/14 packaged equivalent is not widely available.
Is Premphase still manufactured by Pfizer?
Pfizer is associated with the Premarin franchise, but Premphase-specific manufacturing and distribution status is not separately disclosed in Pfizer’s public financial filings.
Is Premphase covered by Medicare Part D?
Coverage depends on the plan formulary, product availability, and whether the plan treats Premphase as a preferred brand, nonpreferred brand, or excluded product. Generic estrogen-progestin alternatives generally receive more favorable formulary treatment.
Could a company acquire rights to Premphase?
A regional license or portfolio transaction is possible, but Premphase alone is unlikely to command significant valuation because it has low growth, substantial generic exposure, and no meaningful patent-based exclusivity.
References
- U.S. Food and Drug Administration. (n.d.). Premphase prescribing information. FDA.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
- Pfizer Inc. (2024). Annual report on Form 10-K for the fiscal year ended December 31, 2023. Pfizer Inc.
-patent-expirations.png "PREMPHASE (PREMARIN;CYCRIN 14/14) drug patent expirations")
